Intermittent BPC-157 combined with senolytic clearance enhances tendon healing by limiting GH‑receptor‑driven senescence

Hypothesis

Intermittent, low‑dose BPC‑157 administration paired with a senolytic regimen (dasatinib + quercetin) will improve tendon repair more than BPC‑157 alone by preventing GH‑receptor‑mediated cellular senescence that otherwise limits extracellular matrix remodeling.

Rationale

BPC‑157 upregulates growth hormone receptor (GHR) in tendon fibroblasts, activating JAK2‑STAT5 signaling and downstream VEGFR2‑driven angiogenesis 1. Persistent GHR signaling can drive fibroblast proliferation toward a senescent phenotype, marked by p16^INK4a^ and SASP secretion, which impairs collagen organization 2. Senolytics selectively eliminate p16^high^ cells, reducing SASP and restoring a pro‑regenerative environment 3. By limiting the duration of GHR activation (e.g., 3‑day on/4‑day off cycles) and clearing senescent fibroblasts, the angiogenic and nitric‑oxide benefits of BPC‑157 are preserved while fibrotic scarring is minimized.

Predictions

1. Tendons treated with BPC‑157 + senolytic will show higher tensile strength and collagen alignment than BPC‑157 alone.
2. Histology will reveal lower p16^INK4a^ positivity and reduced SASP cytokines (IL‑6, MMP‑9) in the combination group.
3. Angiogenic marker (CD31) and nitric‑oxide synthase (eNOS) expression will be comparable between groups, indicating that BPC‑157’s pro‑healing signals are not blunted.
4. No increase in adverse events (e.g., immunogenicity, endotoxin) will be observed when using GMP‑grade peptides and senolytics at established safe doses.

Experimental Design

• Model: Rat Achilles tendon transection model, n=10 per group.
• Groups: (1) Saline control, (2) BPC‑157 (10 µg/kg, subcutaneous, 3 days on/4 days off for 2 weeks), (3) Senolytic (dasatinib 5 mg/kg + quercetin 50 mg/kg, oral, once weekly), (4) BPC‑157 + senolytic (same schedules).
• Outcomes (at 4 weeks):
  • Biomechanical testing: ultimate load and stiffness.
  • Histology: Safranin‑O/Fast‑Green, p16^INK4a^ immunohistochemistry, CD31 staining, eNOS Western blot.
  • ELISA: tendon homogenate IL‑6, MMP‑9, VEGF.
  • Safety: serum anti‑peptide IgG, endotoxin assay (LAL).
• Statistical analysis: One‑way ANOVA with Tukey post‑hoc; significance set at p<0.05.

Potential Outcomes

If the hypothesis holds, the combination group will outperform BPC‑157 alone in mechanical and histologic metrics without increasing safety signals. A null result (no difference) would falsify the premise that GH‑receptor‑driven senescence limits BPC‑157 efficacy, prompting re‑evaluation of dosing strategies. An adverse outcome (e.g., increased inflammation) would suggest senolytic timing is critical and could be adjusted in follow‑up studies.

Implications

Confirming that transient GHR activation coupled with senescent‑cell clearance optimizes BPC‑157’s regenerative actions would provide a mechanistically grounded protocol for future human trials, addressing the current lack of credible clinical data while mitigating theoretical oncogenic and fibrotic risks.